Civic Intelligence

Path Drug Solutions

990 • Fiscal year 2016 • EIN 94-3384500

Jan 01, 2016 to Dec 31, 2016 • Filed on Nov 14, 2017

Organization ProfileWWW.PATH.ORG

View Organization Page

2201 Westlake Avenue No 200Seattle, WA 98121

(206) 285-3500

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

10th percentile

0.00x

Higher debt load relative to assets than 10% of similar nonprofits.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2016

Liabilities / Revenue

47th percentile

0.21x

Higher debt load relative to revenue than 47% of similar nonprofits.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2016

Net Margin

1st percentile

-1413%

Higher net margin than 1% of similar nonprofits.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2016

Top Officer Pay

93rd percentile

$685,314

Higher top officer pay than 93% of similar nonprofits.

Top officer pay equals 316.6% of source-year revenue.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2016

Asset Growth

2nd percentile

-31%

Faster asset growth than 2% of similar nonprofits.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Annualized from 2015 to 2016

Revenue Growth

1st percentile

-97%

Faster revenue growth than 1% of similar nonprofits.

2016 filings • 501(c)3 • $10M-$25M nonprofits • Annualized from 2015 to 2016

Balance Sheet
Liabilities / Assets10th percentile

Assets

Down

$10,229,897

Down $4,617,127 (-31%) from 2015

Net Assets

Down

$10,183,512

Down $3,058,209 (-23%) from 2015

Liabilities

Down

$46,385

Down $1,558,918 (-97%) from 2015

Revenue And Expenses
Liabilities / Revenue47th percentileNet Margin1st percentile

Revenue

Down

$216,478

Down $6,923,237 (-97%) from 2015

Expenses

Down

$3,275,717

Down $2,721,994 (-45%) from 2015

Net Income

Down

-$3,059,239

Down $4,201,243 (-368%) from 2015

Historical Trend

Balance Sheet Trend

Asset Growth2nd percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$60M$40M$20M$0Assets 2010: $26,215,343Liabilities 2010: $4,437,688Net Assets 2010: $21,777,6552010Assets 2011: $24,285,254Liabilities 2011: $1,581,867Net Assets 2011: $22,703,3872011Assets 2012: $28,999,523Liabilities 2012: $2,883,967Net Assets 2012: $26,115,5562012Assets 2013: $42,859,417Liabilities 2013: $977,931Net Assets 2013: $41,881,4862013Assets 2014: $37,978,413Liabilities 2014: $1,584,692Net Assets 2014: $36,393,7212014Assets 2015: $14,847,024Liabilities 2015: $1,605,303Net Assets 2015: $13,241,7212015Assets 2016: $10,229,897Liabilities 2016: $46,385Net Assets 2016: $10,183,5122016Assets 2017: $7,105,262Liabilities 2017: $708,783Net Assets 2017: $6,396,4792017Assets 2018: $0Liabilities 2018: $0Net Assets 2018: $02018

Highlighted filing

2016

Assets$10,229,897
Liabilities$46,385
Net Assets$10,183,512
Open 2016 Filing

Operations Trend

Revenue Growth1st percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$30M$20M$10M$0-$10MExpenses 2010: $17,804,3432010Expenses 2011: $13,676,7372011Expenses 2012: $11,651,8702012Revenue 2013: $24,724,025Expenses 2013: $8,958,738Net Income 2013: $15,765,2872013Revenue 2014: $5,270,106Expenses 2014: $10,759,489Net Income 2014: -$5,489,3832014Revenue 2015: $7,139,715Expenses 2015: $5,997,711Net Income 2015: $1,142,0042015Revenue 2016: $216,478Expenses 2016: $3,275,717Net Income 2016: -$3,059,2392016Revenue 2017: $201,146Expenses 2017: $2,548,179Net Income 2017: -$2,347,0332017Revenue 2018: $2,972,163Expenses 2018: $3,576,203Net Income 2018: -$604,0402018

Highlighted filing

2016

Revenue$216,478
Expenses$3,275,717
Net Income-$3,059,239
Open 2016 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2016 to Dec 31, 2016
Signed
Nov 14, 2017
Return Version
2016v3.0
Gross Receipts
$216,478
Mission and Program Overview

Mission

Path drug solutions (pds) develops and advances safe and effective medicines for the prevention and treatment of diseases disproportionately affecting women and children in low-resource settings. We work with a variety of public- and private-sector stakeholders to build cross-sector collaborations, secure intellectual property, revisit promising drugs or drug candidates that have been set aside for nonmedical reasons (e.g., lack of earning potential), and harness scientific and manufacturing capacity in high- and low- or middle-income countries to ensure drugs are available, accessible, and affordable to all those who need them.

SEE PART III, LINE 1.

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$12,733,112--
Accounts Receivable$1,933$8,126,443▲ $8,124,510
Pledges and Grants Receivable$2,045,216$2,048,216▲ $3,000
Cash and Non-Interest-Bearing Accounts$49,655$48,385▼ $1,270
Investments in Publicly Traded Securities$3,736$4,766▲ $1,030
Land, Buildings, and Equipment, Net$10,020$2,064▼ $7,956
Prepaid Expenses and Deferred Charges$3,352$23▼ $3,329
Total Assets$14,847,024$10,229,897▼ $4,617,127
Liabilities
Accounts Payable and Accrued Expenses$1,605,303$46,385▼ $1,558,918
Total Liabilities$1,605,303$46,385▼ $1,558,918
Net Assets / Fund Balance
Temporarily Rstr Net Assets$12,597,329$9,692,766▼ $2,904,563
Unrestricted Net Assets$644,392$490,746▼ $153,646
Total Net Assets Fund Balance$13,241,721$10,183,512▼ $3,058,209
Total Liabilities and Net Assets / Fund Balance$14,847,024$10,229,897▼ $4,617,127

Asset Categories

AssetBook ValueDepreciationBasis
Equipment$2,064$21,805$23,869
Compensation and Service Providers
Top Officer Pay93rd percentile

Board Members and Trustees

NameTitle
Stephen B DavisPresident & CEO
Dan HartmanDirector
David C KaslowDirector
Jorge FloresDirector
Keith ChirgwinDirector
Ken DuncanDirector
Daniel LasterSecretary
Olivia D PoliusTreasurer & CFO
Revenue and Support

Revenue Composition

Contributions and Grants
$163,077
Program Service Revenue
$0
Investment Income
$50,401
Other Revenue
$3,000
Change in Net Assets
$-3,059,239
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$2,597,185
Other Expenses$678,532
Professional Fundraising Fees$0
Salaries, Compensation, and Employee Benefits$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Grants to Domestic Orgs$2,358,006--$2,358,006
Foreign Grants$239,179--$239,179
Fees for Services Other$222,757$1,168-$223,925
Travel$191,779--$191,779
Occupancy-$107,956-$107,956
Office Expenses$18,064$195-$18,259
Conferences and Meetings$17,510--$17,510
Fees for Services Legal$8,298--$8,298
Depreciation Depletion$1,682$6,275-$7,957
Information Technology$4,693--$4,693
Insurance$1,100$3,352-$4,452
Advertising$2,254--$2,254
Other Expenses$278$1,585-$278
All Other Expenses$-184,187$183,979-$-208
Total Functional Expenses$2,971,058$304,659$0$3,275,717
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
PathSeattle, WA501(c)(3)General Support$2,358,006

International Summary

Offices
0
Employees
5
Spending
$479,360

International Compliance

Foreign grant records maintained
Yes
Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
Yes

International Activities

RegionActivityServicesOfficesEmployeesSpending
South AsiaGrantmakingEssential Medicine00$239,179
South AsiaProgram ServicesInternational Development05$125,848
EuropeProgram ServicesEssential Medicine00$113,665
Sub-saharan AfricaProgram Services-00$647
East Asia and the PacificProgram ServicesEssential Medicine00$21
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
No
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
Yes
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section B, Line 11B

“The form 990 was prepared by an outside accounting firm (gelman, rosenberg & freedman cpas) using information provided by path accounting services staff. Path senior management reviewed the draft form. A copy of the draft was sent to path's board of directors for comment. After the comment period, the chief financial officer signed and filed the return.”

Form 990, Part VI, Section B, Line 12C

“Pds has a written conflict of interest policy under which all pds board members and officers must complete a conflict of interest disclosure form each year. Pds does not have employees. Pds is a supporting organization to path within the meaning of internal review code section 509(a)(3) and contracts with path for management services. Path has a written conflict of interest policy under which all path board members, officers, and staff at higher than a designated level must complete a conflict of interest disclosure form each year. All pds and path disclosure forms are reviewed and kept on file. A conflict management plan is developed for any employee with a significant actual or perceived conflict of interest.”

Form 990, Part VI, Section C, Line 19

“Pds makes its governing documents, conflict of interest policy, and financial statements available to the public upon request.”

Filing and Contact Details

Filer

Filer Name
Path Drug Solutions
EIN
94-3384500
Phone
2062853500
Address
2201 WESTLAKE AVENUE NO 200, SEATTLE, WA 98121

Signing Officer

Name
Olivia D Polius
Title
Chief Financial Officer
Phone
2062853500
Signed
2017-11-14
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Olivia D Polius
Formed
2000
Legal Domicile
CA
Voting Board Members
8
Independent Board Members
3
Employees
0
Volunteers
0

Preparer

Firm
Gelman Rosenberg & Freedman
Address
4550 MONTGOMERY AVE SUITE 650N, BETHESDA, MD 20814-2930
Phone
3019519090
Raw XML AppendixShowing 400 of 634 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt01605303
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt046385
IRS990/AccountsReceivableGrp/BOYAmt01933
IRS990/AccountsReceivableGrp/EOYAmt08126443
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0SEE PART III, LINE 1.
IRS990/AdvertisingGrp/ProgramServicesAmt02254
IRS990/AdvertisingGrp/TotalAmt02254
IRS990/AllOtherExpensesGrp/ManagementAndGeneralAmt0183979
IRS990/AllOtherExpensesGrp/ProgramServicesAmt0-184187
IRS990/AllOtherExpensesGrp/TotalAmt0-208
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0OLIVIA POLIUS CHIEF FINANCIAL OFFICER
IRS990/BooksInCareOfDetail/PhoneNum02062853500
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt02201 WESTLAKE AVENUE SUITE 200
IRS990/BooksInCareOfDetail/USAddress/CityNm0SEATTLE
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0WA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd098121
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt049655
IRS990/CashNonInterestBearingGrp/EOYAmt048385
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd00
IRS990/CompensationProcessOtherInd00
IRS990/ConferencesMeetingsGrp/ProgramServicesAmt017510
IRS990/ConferencesMeetingsGrp/TotalAmt017510
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd01
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt0163077
IRS990/CYGrantsAndSimilarPaidAmt02597185
IRS990/CYInvestmentIncomeAmt050401
IRS990/CYOtherExpensesAmt0678532
IRS990/CYOtherRevenueAmt03000
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt0-3059239
IRS990/CYSalariesCompEmpBnftPaidAmt00
IRS990/CYTotalExpensesAmt03275717
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt0216478
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd00
IRS990/DelegationOfMgmtDutiesInd00
IRS990/DepreciationDepletionGrp/ManagementAndGeneralAmt06275
IRS990/DepreciationDepletionGrp/ProgramServicesAmt01682
IRS990/DepreciationDepletionGrp/TotalAmt07957
IRS990/Desc0ESSENTIAL MEDICINES: PDS PARTNERED WITH COLLEAGUES IN BANGLADESH TO HELP LAUNCH THE DIARRHEA INNOVATIONS GROUP, A GLOBAL NETWORK COMMITTED TO REDUCING CHILD DEATHS FROM DIARRHEAL DISEASE. THE GROUP'S PRIMARY GOAL IS TO ACCELERATE THE DEVELOPMENT AND ADOPTION OF NEW DIAGNOSTIC AND THERAPEUTIC TECHNOLOGIES WITH THE GREATEST POTENTIAL TO REDUCE CHILD DEATHS FROM DIARRHEAL DISEASE IN COUNTRIES WITH THE HIGHEST DISEASE BURDEN.TO ADDRESS CRYPTOSPORIDIUM INFECTION, ONE OF THE LEADING CAUSES OF DIARRHEAL DISEASE AMONG YOUNG CHILDREN IN LOW-RESOURCE SETTINGS, PDS WORKED WITH ACADEMIC RESEARCHERS AND OTHERS TO ADVANCE RESEARCH AND DEVELOPMENT OF DRUG CANDIDATES TO REDUCE MORTALITY AND MORBIDITY. TO COMBAT MALARIA WORLDWIDE, PDS CONTINUED WORK TO ENSURE THAT SUFFICIENT SOURCES AND QUANTITIES OF ARTEMISININ, A KEY INGREDIENT IN GOLD-STANDARD MALARIA TREATMENTS, ARE AVAILABLE TO FULLY SUPPORT CURRENT AND FUTURE USE OF ARTEMISININ-BASED COMBINATION THERAPY IN GLOBAL MALARIA CONTROL AND ELIMINATION PROGRAMS. PDS ALSO CONTINUED TO ADVANCE A LONG-ACTING INJECTABLE DRUG THAT MAY HELP PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE (AN APPROACH CALLED "PRE-EXPOSURE PROPHYLAXIS, OR "PREP"). PDS PROVIDED REGULATORY SPONSORSHIP OF A PHASE 2 TRIAL TO EVALUATE THE SAFETY AND ACCEPTABILITY OF INTRAMUSCULAR INJECTIONS. BY EARLY 2016, ALL FOUR CLINICAL TRIAL SITES IN THE UNITED STATES, SOUTH AFRICA, AND ZIMBABWE HAD COMPLETED ENROLLMENT OF PARTICIPANTS, AND PDS HAD CONDUCTED SITE VISITS TO CONFIRM SITE QUALITY AND COMPLIANCE WITH THE STUDY PROTOCOL.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt00
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt02373686
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesLegalGrp/ProgramServicesAmt08298
IRS990/FeesForServicesLegalGrp/TotalAmt08298
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt01168
IRS990/FeesForServicesOtherGrp/ProgramServicesAmt0222757
IRS990/FeesForServicesOtherGrp/TotalAmt0223925
IRS990/ForeignActivitiesInd01
IRS990/ForeignCountryCd0IN
IRS990/ForeignFinancialAccountInd01
IRS990/ForeignGrantsGrp/ProgramServicesAmt0239179
IRS990/ForeignGrantsGrp/TotalAmt0239179
IRS990/ForeignOfficeInd01
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt039.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt139.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt239.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt339.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt439.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt50.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt60.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt70.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt01.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt52.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt62.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt72.00
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd7X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt062041
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt148805
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt242894
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt363492
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt438905
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt70
IRS990/Form990PartVIISectionAGrp/PersonNm0STEPHEN B DAVIS
IRS990/Form990PartVIISectionAGrp/PersonNm1OLIVIA D POLIUS
IRS990/Form990PartVIISectionAGrp/PersonNm2DANIEL LASTER
IRS990/Form990PartVIISectionAGrp/PersonNm3DAVID C KASLOW
IRS990/Form990PartVIISectionAGrp/PersonNm4JORGE FLORES
IRS990/Form990PartVIISectionAGrp/PersonNm5KEITH CHIRGWIN
IRS990/Form990PartVIISectionAGrp/PersonNm6KEN DUNCAN
IRS990/Form990PartVIISectionAGrp/PersonNm7DAN HARTMAN
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt0623273
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt1303385
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt2304582
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt3354854
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt4266659
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt70
IRS990/Form990PartVIISectionAGrp/TitleTxt0PRESIDENT & CEO
IRS990/Form990PartVIISectionAGrp/TitleTxt1TREASURER & CFO
IRS990/Form990PartVIISectionAGrp/TitleTxt2SECRETARY
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt7DIRECTOR
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr02000
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedBasisGrp/ConsolidatedBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd00
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt08
IRS990/GrantAmt02127088
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt02358006
IRS990/GrantsToDomesticOrgsGrp/TotalAmt02358006
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt0216478
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd00
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt03
IRS990/IndivRcvdGreaterThan100KCnt00
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InformationTechnologyGrp/ProgramServicesAmt04693
IRS990/InformationTechnologyGrp/TotalAmt04693
IRS990/InsuranceGrp/ManagementAndGeneralAmt03352
IRS990/InsuranceGrp/ProgramServicesAmt01100
IRS990/InsuranceGrp/TotalAmt04452
IRS990/InvestmentIncomeGrp/ExclusionAmt050401
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt050401
IRS990/InvestmentInJointVentureInd00
IRS990/InvestmentsPubTradedSecGrp/BOYAmt03736
IRS990/InvestmentsPubTradedSecGrp/EOYAmt04766
IRS990/IRPDocumentCnt00
IRS990/IRPDocumentW2GCnt00
IRS990/LandBldgEquipAccumDeprecAmt021805
IRS990/LandBldgEquipBasisNetGrp/BOYAmt010020
IRS990/LandBldgEquipBasisNetGrp/EOYAmt02064
IRS990/LandBldgEquipCostOrOtherBssAmt023869
IRS990/LegalDomicileStateCd0CA
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0PATH DRUG SOLUTIONS (PDS) DEVELOPS AND ADVANCES SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES TO ENSURE DRUGS ARE AVAILABLE, ACCESSIBLE, AND AFFORDABLE TO ALL THOSE WHO NEED THEM.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt013241721
IRS990/NetAssetsOrFundBalancesEOYAmt010183512
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt01030
IRS990/NondeductibleContributionsInd00
IRS990/OccupancyGrp/ManagementAndGeneralAmt0107956
IRS990/OccupancyGrp/TotalAmt0107956
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt0195
IRS990/OfficeExpensesGrp/ProgramServicesAmt018064
IRS990/OfficeExpensesGrp/TotalAmt018259
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsSFAS117Ind0X
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherExpensesGrp/Desc0SUBCONTRACTS
IRS990/OtherExpensesGrp/Desc1EQUIPMENT R&M
IRS990/OtherExpensesGrp/Desc2OFFSITE STORAGE
IRS990/OtherExpensesGrp/Desc3APPRECIATION GIFTS
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt0149
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt11585
IRS990/OtherExpensesGrp/ProgramServicesAmt073591
IRS990/OtherExpensesGrp/ProgramServicesAmt115527
IRS990/OtherExpensesGrp/ProgramServicesAmt2527
IRS990/OtherExpensesGrp/ProgramServicesAmt3278
IRS990/OtherExpensesGrp/TotalAmt073591
IRS990/OtherExpensesGrp/TotalAmt115676
IRS990/OtherExpensesGrp/TotalAmt22112
IRS990/OtherExpensesGrp/TotalAmt3278
IRS990/OtherRevenueMiscGrp/BusinessCd0900099
IRS990/OtherRevenueMiscGrp/Desc0REIMBURSEMENT
IRS990/OtherRevenueMiscGrp/ExclusionAmt03000
IRS990/OtherRevenueMiscGrp/TotalRevenueColumnAmt03000
IRS990/OtherRevenueTotalAmt03000
IRS990/OtherWebsiteInd0X
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PledgesAndGrantsReceivableGrp/BOYAmt02045216
IRS990/PledgesAndGrantsReceivableGrp/EOYAmt02048216
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt03352
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt023
IRS990/PrincipalOfficerNm0OLIVIA D POLIUS
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0INTERNATIONAL DEVELOPMENT: IN 2016, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS (VL), ALSO KNOWN AS KALA-AZAR. VL IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF UNTREATED. IN COLLABORATION WITH PARTNERS IN BANGLADESH AND NEPAL, PDS CONTINUED WORK TO STRENGTHEN NATIONAL PHARMACOVIGILANCE (PV) PROGRAMS FOR VL ELIMINATION. THE PV PROGRAMS AIM TO IMPROVE PATIENT SAFETY AND CARE ASSOCIATED WITH THE USE OF VL DRUGS, AND HAVE BEEN ACCLAIMED BY THE GOVERNMENTS OF NEPAL AND BANGLADESH. PDS ALSO ADVANCED A POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL)/VL RELAPSE OBSERVATION STUDY IN BANGLADESH. PKDL SURVEILLANCE IS ESPECIALLY IMPORTANT BECAUSE THE DISEASE SERVES AS A SIGNIFICANT VECTOR FOR OVERALL VL TRANSMISSION. INTERIM DATA FOR THE MONOTHERAPY TREATMENT ARMS WERE DISSEMINATED IN 2016 WITH AN OBSERVATION OF A STRONG RELATIONSHIP BETWEEN PKDL/VL RELAPSE INCIDENCE AND THE CURRENT PRIMARY VL TREATMENT. TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0597372
IRS990/ProgSrvcAccomActy2Grp/GrantAmt0470097
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt07126779
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt04768944
IRS990/PYInvestmentIncomeAmt012936
IRS990/PYOtherExpensesAmt01228767
IRS990/PYOtherRevenueAmt00
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt01142004
IRS990/PYSalariesCompEmpBnftPaidAmt00
IRS990/PYTotalExpensesAmt05997711
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt07139715
IRS990/QuidProQuoContributionsInd00
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReconcilationRevenueExpnssAmt0-3059239
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd01
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/RelatedOrganizationsAmt0163077
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd01
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/SavingsAndTempCashInvstGrp/BOYAmt012733112
IRS990ScheduleA/Form990SchASupportingOrgGrp/Contribution35ControlledInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionControllerInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionFamilyInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ControlledDisqualifiedPrsnInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnControllIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnOwnrIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ExcessBusinessHoldingsRulesInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ListedByNameGoverningDocInd01
IRS990ScheduleA/Form990SchASupportingOrgGrp/LoanDisqualifiedPersonInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/OrganizationChangeSuprtOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/PaymentSubstantialContribtrInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgNotOrganizedUSInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgSectionC456Ind00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportNonSupportedOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SuprtOrgNoIRSDeterminationInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/OperateBenefitNonSuprtOrgInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/PowerAppointMajorityDirTrstInd01
IRS990ScheduleA/OtherSupportSumAmt00
IRS990ScheduleA/SupportedOrganizationsCnt01
IRS990ScheduleA/SupportedOrganizationsTotalCnt01
IRS990ScheduleA/SupportedOrgInformationGrp/EIN0911157127
IRS990ScheduleA/SupportedOrgInformationGrp/GoverningDocumentListedInd01
IRS990ScheduleA/SupportedOrgInformationGrp/OrganizationTypeCd07
IRS990ScheduleA/SupportedOrgInformationGrp/OtherSupportAmt00
IRS990ScheduleA/SupportedOrgInformationGrp/SupportAmt03275717
IRS990ScheduleA/SupportedOrgInformationGrp/SupportedOrganizationName/BusinessNameLine1Txt0PATH
IRS990ScheduleA/SupportingOrganization509a3Ind0X
IRS990ScheduleA/SupportingOrgType1Ind0X
IRS990ScheduleA/SupportSumAmt03275717
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990/ScheduleBRequiredInd01
IRS990ScheduleD/EquipmentGrp/BookValueAmt02064
IRS990ScheduleD/EquipmentGrp/DepreciationAmt021805
IRS990ScheduleD/EquipmentGrp/OtherCostOrOtherBasisAmt023869
IRS990ScheduleD/TotalBookValueLandBuildingsAmt02064
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt25
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt20
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt021
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt1113665
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt2125848
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt3239179
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt4647
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0EAST ASIA AND THE PACIFIC
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt1EUROPE
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt2SOUTH ASIA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt3SOUTH ASIA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt4SUB-SAHARAN AFRICA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0ESSENTIAL MEDICINE
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt1ESSENTIAL MEDICINE
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt2INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt3ESSENTIAL MEDICINE
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt1PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt2PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt3GRANTMAKING
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt4PROGRAM SERVICES
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinutationTotalEmployeeCnt00
IRS990ScheduleF/ContinutationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantRecordsMaintainedInd01
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt041916
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt130083
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt2154056
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt38579
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt1CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt2CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt3CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt1INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt2INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt3INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0SOUTH ASIA
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt1SOUTH ASIA
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt2SOUTH ASIA
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt3SOUTH ASIA
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt05
IRS990ScheduleF/SubtotalOfficesCnt00
IRS990ScheduleF/SubtotalSpentAmt0479360
IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt0PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE THAT GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND ACHIEVES PERFORMANCE GOALS.
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleF/Total501c3OrgCnt04
IRS990ScheduleF/TotalEmployeeCnt05
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalOtherOrgCnt00
IRS990ScheduleF/TotalSpentAmt0479360
IRS990ScheduleF/TransferToForeignCorpInd01
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt02358006
IRS990ScheduleI/RecipientTable/IRCSectionDesc0501(C)(3)
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0GENERAL SUPPORT
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0PATH
IRS990ScheduleI/RecipientTable/RecipientEIN0911157127
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt02201 WESTLAKE AVENUE SUITE 200
IRS990ScheduleI/RecipientTable/USAddress/CityNm0SEATTLE
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd0WA
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd098121
IRS990ScheduleI/SupplementalInformationDetail/ExplanationTxt0PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE THAT GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT PERFORMANCE GOALS ARE ACHIEVED.
IRS990ScheduleI/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleI/Total501c3OrgCnt01
IRS990ScheduleI/TotalOtherOrgCnt00
IRS990ScheduleJ/AnyNonFixedPaymentsInd00
IRS990ScheduleJ/CompBasedOnRevenueOfFlngOrgInd00
IRS990ScheduleJ/CompBsdNetEarnsFlngOrgInd00
IRS990ScheduleJ/CompBsdNetEarnsRltdOrgsInd00
IRS990ScheduleJ/CompBsdOnRevRelatedOrgsInd00
IRS990ScheduleJ/EquityBasedCompArrngmInd00
IRS990ScheduleJ/InitialContractExceptionInd00

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2016 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$10,229,897
Liabilities
$46,385
Net assets
$10,183,512
Revenue
$216,478
Expenses
$3,275,717
Net income
-$3,059,239
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2018Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$2.97$3.58$0.60
2017Detailed filing. Detailed filing data is available for this year.$7.11$0.71$6.40$0.20$2.55$2.35
2016Detailed filing. Detailed filing data is available for this year.$10.2$0.05$10.2$0.22$3.28$3.06
2015Detailed filing. Detailed filing data is available for this year.$14.8$1.61$13.2$7.14$6.00$1.14
2014Detailed filing. Detailed filing data is available for this year.$38.0$1.58$36.4$5.27$10.8$5.49
2013Detailed filing. Detailed filing data is available for this year.$42.9$0.98$41.9$24.7$8.96$15.8
2012Facts available. Structured filing facts are available, but richer extracted sections are limited.$29.0$2.88$26.1$11.7
2011Facts available. Structured filing facts are available, but richer extracted sections are limited.$24.3$1.58$22.7$13.7
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$26.2$4.44$21.8$17.8